# A randomised double-blind prospective study to compare the intubating conditions with remifentanil (4 ug/mkg) and either propofol (2 mg/kg) or etomidate (0.3 mg/kg)

Submission date 12/09/2003	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<ul> <li>Statistical analysis plan</li> <li>Results</li> </ul>
Last Edited 11/12/2014	<b>Condition category</b> Surgery	<ul> <li>Individual participant data</li> <li>Record updated in last year</li> </ul>

### Plain English summary of protocol

Not provided at time of registration

# **Contact information**

# Type(s)

Scientific

### Contact name

Dr Ian McNeil

#### **Contact details**

Department of Anaesthesia Hull Royal Infirmary Anlaby Road Hull United Kingdom HU3 2 JZ

# Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

#### N0084113942

## Study information

#### Scientific Title

A randomised double-blind prospective study to compare the intubating conditions with remifentanil (4 ug/mkg) and either propofol (2 mg/kg) or etomidate (0.3 mg/kg)

#### **Study objectives**

To investigate whether there is a role for etomidate for intubation without muscle relaxants?
 Is it more stable than propofol?

**Ethics approval required** Old ethics approval format

**Ethics approval(s)** Not provided at time of registration

**Study design** Randomised controlled trial

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Hospital

**Study type(s)** Treatment

Participant information sheet

Health condition(s) or problem(s) studied Surgery: Intubation

#### Interventions

Remifentanil and etomidate
 Remifentanil and propofol

Both the patients and the intubating anaesthetist will be blinded to the induction agents administered by a second anaesthetist.

Intervention Type

Drug

**Phase** Not Applicable

#### Drug/device/biological/vaccine name(s)

Remifentanil, etomidate, propofol

#### Primary outcome measure

The end points are: 1. Intubating conditions 2. Cardiovascular stability

**Secondary outcome measures** Not provided at time of registration

Overall study start date 01/08/2002

**Completion date** 01/06/2004

# Eligibility

#### Key inclusion criteria

40 American Society of Anesthesiologists (ASA) 1 and 2 non-obese (Body Mass Index [BMI] <30) elective surgical patients aged between 18 and 65 years. They must require intubation for their proposed surgery.

Participant type(s) Patient

**Age group** Adult

**Lower age limit** 18 Years

**Upper age limit** 65 Years

### Sex

Both

**Target number of participants** 40

**Key exclusion criteria** Not provided at time of registration

Date of first enrolment 01/08/2002

Date of final enrolment

01/06/2004

### Locations

**Countries of recruitment** United Kingdom

**Study participating centre Hull Royal Infirmary** Hull United Kingdom HU3 2 JZ

### Sponsor information

**Organisation** Department of Health (UK)

**Sponsor details** Richmond House 79 Whitehall London United Kingdom SW1A 2NL

#### Sponsor type

Government

Website http://www.doh.gov.uk

### Funder(s)

**Funder type** Government

**Funder Name** The North and South Bank Research and Development Consortium (UK)

### **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration